Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
QUIA PHARMA ABFRA:99B0 Equity-to-Asset is 0.42 as of Jun. 2025, which is 17% above its 10-year median of 0.36. The stock has 3 warning signs investors should review.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. QUIA PHARMA AB's Total Stockholders Equity for the quarter that ended in Jun. 2025 was €0.58 Mil. QUIA PHARMA AB's Total Assets for the quarter that ended in Jun. 2025 was €1.37 Mil.
The historical rank and industry rank for QUIA PHARMA AB's Equity-to-Asset or its related term are showing as below:
FRA:99B0'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.25 Med: 0.36 Max: 0.92
Current: 0.42
During the past 13 years, the highest Equity to Asset Ratio of QUIA PHARMA AB was 0.92. The lowest was -1.25. And the median was 0.36.
FRA:99B0's Equity-to-Asset is not ranked
in the Biotechnology industry.
Industry Median: 0.69
vs FRA:99B0: 0.42
QUIA PHARMA AB (FRA:99B0) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
QUIA PHARMA AB Equity-to-Asset Related Terms
QUIA PHARMA AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for QUIA PHARMA AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:99B0 vs VRTX, REGN, ALNY: Equity-to-Asset Comparison
For the Biotechnology subindustry, QUIA PHARMA AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
QUIA PHARMA AB Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, QUIA PHARMA AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where QUIA PHARMA AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
QUIA PHARMA AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
QUIA PHARMA AB (FRA:99B0) has a Equity-to-Asset of 0.42 as of Jun. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on QUIA PHARMA AB and its competitors. This is 17% above median its historical median of 0.36.
Is QUIA PHARMA AB's Equity-to-Asset too high?
QUIA PHARMA AB's current Equity-to-Asset of 0.42 is 17% above median its 10-year median of 0.36. The Biotechnology industry median Equity-to-Asset is 0.69. QUIA PHARMA AB's value of 0.42 is 39.1% below this industry median.
How does QUIA PHARMA AB's Equity-to-Asset compare to VRTX and REGN?
QUIA PHARMA AB's Equity-to-Asset of 0.42 can be compared against companies in the Biotechnology industry. The industry median Equity-to-Asset is 0.69. QUIA PHARMA AB's value of 0.42 is 39.1% below this benchmark. While the company's 10-year median is 0.36 vs. the industry median of 0.69, QUIA PHARMA AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. QUIA PHARMA AB's current Equity-to-Asset of 0.42 is 39.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on QUIA PHARMA AB and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. QUIA PHARMA AB's current Equity-to-Asset is 0.42, which is 17% above median its own 10-year median of 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is QUIA PHARMA AB stock overvalued right now?
QUIA PHARMA AB (FRA:99B0) has a current Equity-to-Asset of 0.42. The current Equity-to-Asset is 0.42, which is 17% above median its 10-year median of 0.36 and 39.1% below the Biotechnology industry median of 0.69. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For QUIA PHARMA AB (FRA:99B0), the current Equity-to-Asset is 0.42 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
QUIA PHARMA AB is a development company for pharmaceuticals based on a patented drug delivery platform, Uni-Qleaver. The company develops improved and patentable forms of drugs under development or already approved by pharmaceutical authorities. These refined and enhanced forms of medicine are based on the Company's exceptional and patented technology platform. In addition to this, the Company offers multinational sales of omega-3, astaxin and collagen through Amazon.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:99B0 has been successfully added to your 
